국가: 캐나다
언어: 영어
출처: Health Canada
ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE)
JAMP PHARMA CORPORATION
N06BA09
ATOMOXETINE
60MG
CAPSULE
ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE) 60MG
ORAL
15G/50G
Prescription
MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS
Active ingredient group (AIG) number: 0150434005; AHFS:
APPROVED
2020-10-20
JAMP ATOMOXETINE Product Monograph Page 1 PRODUCT MONOGRAPH PR JAMP ATOMOXETINE Atomoxetine Capsules 10, 18, 25, 40, 60, 80 and 100 mg atomoxetine (as atomoxetine hydrochloride) House standard SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITOR FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) JAMP Pharma Corporation 1310, rue Nobel Boucherville, Québec J4B 5H3 Date of Approval: October 19, 2020 Submission Control No 235031 JAMP ATOMOXETINE Product Monograph Page 2 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ................................................... 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE .......................................................................... 3 CONTRAINDICATIONS ............................................................................................... 4 WARNINGS AND PRECAUTIONS ............................................................................. 5 ADVERSE REACTIONS ............................................................................................. 12 DRUG ABUSE AND DEPENDENCE ......................................................................... 22 DRUG INTERACTIONS .............................................................................................. 23 DOSAGE AND ADMINISTRATION .......................................................................... 24 OVERDOSAGE ............................................................................................................ 27 ACTION AND CLINICAL PHARMACOLOGY ........................................................ 28 STORAGE AND STABILITY ..................................................................................... 32 DOSAGE FORMS, COMPOSITION AND PACKAGING ......................................... 33 PART II: SCIENTIFIC INFORMATION ......................................................................... 34 PHARMACEUTICAL INFORMATION ........................................................ 전체 문서 읽기